A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
about
Immunotherapy in endometrial cancer - an evolving therapeutic paradigmMolecular staging of gynecological cancer: What is the future?A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Recent Advances in Endometrial Cancer.Endometrial cancer: redefining the molecular-targeted approach.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsThe future role of molecular staging in gynecologic cancer.New therapies for advanced, recurrent, and metastatic endometrial cancers.Synthetically lethal nanoparticles for treatment of endometrial cancer.Clinical trials in gynecologic oncology: Past, present, and future.Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.Nintedanib: first global approval.
P2860
Q27020910-7E12B379-5D4D-428A-A0A6-D638EC01B4E4Q35940829-71692E40-E504-41A7-B611-01FF35964F54Q36407018-0F6FDA97-1423-4B9D-8CC4-D911A1300390Q37620470-6B7F77D1-536B-439C-9FCA-FE43491F81DEQ38454955-5A6A25BB-F665-45FC-B77E-593DC3A2B608Q38631272-0563B05C-AF59-4B7D-998D-096F8820BCADQ38669565-09F93983-0A75-479F-96D4-CD323FC7461DQ38670417-8A66045E-464E-48FA-A74A-935198D7FF9CQ38753038-8AFCA12D-88E4-40E7-AEEF-4054592123FDQ38895754-7922181A-3A13-4A9A-8C4B-F68EA5E28BE5Q38957038-91EA6F4D-33EA-45DC-8482-1E6322C2F7B8Q47103210-C5066661-4D71-4499-8B9F-1DD35F50708BQ47370432-E7D0AD08-F3A4-4728-837B-6F0343355F2FQ47796770-D000EBEA-25C3-4C55-8829-1B22D432EA44Q48328979-A01D63A5-B504-4FE0-B16F-959DCC692519Q54307476-C4A7D365-0925-4703-B48F-B2E7022A1724
P2860
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@ast
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@en
type
label
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@ast
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@en
prefLabel
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@ast
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@en
P2093
P2860
P50
P1433
P1476
A phase II evaluation of ninte ...... ecologic Oncology Group Study.
@en
P2093
Don S Dizon
Jeanne M Schilder
Kathryn F McGonigle
Michael W Sill
Zia Rahman
P2860
P304
P356
10.1016/J.YGYNO.2014.10.001
P407
P577
2014-10-13T00:00:00Z